Bone marrow fibrosis and early hematological response as predictors of poor outcome in azacitidine treated high risk-MDS/AML patients

Azacitidine (AZA) treatment is effective treatment for patients with myeloid disorders, and factors predictive of treatment outcome are under investigation. Little is known about the impact of bone marrow (BM) fibrosis on response to AZA therapy. We retrospectively evaluated clinical predictors of overall survival (OS) and overall response rate (ORR) for patients treated with AZA in a real-life cohort. We evaluated 94 consecutive patients treated with AZA outside of clinical trials (75mg/m2/day for 7 days every 28 days; 5+2+2 schedule), from June 2009 –February 2016.
Source: Seminars in Hematology - Category: Hematology Authors: Tags: Research article Source Type: research